Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer.
McCleary NJ, Sato K, Nishihara R, Inamura K, Morikawa T, Zhang X, Wu K, Yamauchi M, Kim SA, Sukawa Y, Mima K, Qian ZR, Fuchs CS, Ogino S, Meyerhardt JA. McCleary NJ, et al. Clin Cancer Res. 2016 Mar 15;22(6):1489-98. doi: 10.1158/1078-0432.CCR-15-0946. Epub 2015 Oct 21. Clin Cancer Res. 2016. PMID: 26490308 Free PMC article.
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS. Ogino S, et al. Among authors: mccleary nj. Clin Cancer Res. 2012 Feb 1;18(3):890-900. doi: 10.1158/1078-0432.CCR-11-2246. Epub 2011 Dec 6. Clin Cancer Res. 2012. PMID: 22147942 Free PMC article. Clinical Trial.
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG. Zhu AX, et al. Among authors: mccleary nj. Clin Cancer Res. 2013 Mar 15;19(6):1557-66. doi: 10.1158/1078-0432.CCR-12-3041. Epub 2013 Jan 29. Clin Cancer Res. 2013. PMID: 23362324 Free PMC article. Clinical Trial.
Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients.
Rubinson DA, Hochster HS, Ryan DP, Wolpin BM, McCleary NJ, Abrams TA, Chan JA, Iqbal S, Lenz HJ, Lim D, Rose J, Bekaii-Saab T, Chen HX, Fuchs CS, Ng K. Rubinson DA, et al. Among authors: mccleary nj. Invest New Drugs. 2014 Feb;32(1):113-22. doi: 10.1007/s10637-013-9956-5. Epub 2013 Apr 9. Invest New Drugs. 2014. PMID: 23568716 Free PMC article. Clinical Trial.
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.
Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS. Wolpin BM, et al. Among authors: mccleary nj. Oncologist. 2013;18(4):377-8. doi: 10.1634/theoncologist.2012-0378. Epub 2013 Apr 11. Oncologist. 2013. PMID: 23580238 Free PMC article. Clinical Trial.
59 results